• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why Bed Bath & Beyond Shares Are Trading Lower By 15%? Here Are Other Stocks Moving In Thursday's Mid-Day Session

    3/30/23 12:43:14 PM ET
    $ANGO
    $ARCT
    $AXDX
    $BBBY
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ANGO alert in real time by email

    Gainers

    • SCYNEXIS, Inc. (NASDAQ:SCYX) shares climbed 68% to $2.8184 after the company announced an exclusive license agreement with GSK for Brexafemme, in which the company will receive an upfront payment of $90 million.
    • Palisade Bio, Inc. (NASDAQ:PALI) rose 49% to $2.51 after Maxim Group upgraded the stock from Hold to Buy and announced a $50 price target.
    • National CineMedia, Inc. (NASDAQ:NCMI) jumped 32.1% to $0.1510. National CineMedia is preparing for Chapter 11 filing, the Wall Street Journal reported last week.
    • Boxed, Inc. (NYSE:BOXD) jumped 31.9% to $0.2120 after declining 6% on Wednesday. Boxed recently said it is evaluating potentially filing for relief under the U.S. Bankruptcy Code and other strategic alternatives.
    • Accelerate Diagnostics, Inc. (NASDAQ:AXDX) surged 27.5% to $0.64 after the company reported better-than-expected Q4 sales results.
    • EVgo, Inc. (NASDAQ:EVGO) shares gained 24.4% to $7.17 after the company reported that fourth-quarter sales nearly quadrupled year-on-year to $27.30 million, beating the consensus of $21.82 million.
    • Toro Corp. (NASDAQ:TORO) climbed 21% to $2.36 after gaining around 20% on Wednesday.
    • Puma Biotechnology, Inc. (NASDAQ:PBYI) gained 20.6% to $3.0750.
    • Safe & Green Holdings Corp. (NASDAQ:SGBX) shares climbed 18.8% to $0.96 after the company reported Q4 results.
    • Conformis, Inc. (NASDAQ:CFMS) jumped 18.5% to $1.79. Conformis recently posted upbeat quarterly results.
    • Digital Media Solutions, Inc. (NYSE:DMS) rose 18.5% to $0.9507. The company recently signed an agreement to acquire the HomeQuote.io home services marketplace from Customer Direct Group, along with their brand direct international ad network.
    • YS Biopharma Co., Ltd. (NASDAQ:YS) gained 17.2% to $2.3797.
    • Eos Energy Enterprises, Inc. (NASDAQ:EOSE) rose 17.1% to $2.46. Eos Energy Enterprises recently reported worse-than-expected Q4 sales results.
    • Adamas One Corp. (NASDAQ:JEWL) gained 15.2% to $0.91.
    • F45 Training Holdings Inc. (NYSE:FXLV) jumped 15% to $1.42.
    • Sprinklr, Inc. (NYSE:CXM) gained 15% to $12.52 after the company reported better-than-expected Q4 EPS and sales results.
    • LightInTheBox Holding Co., Ltd. (NYSE:LITB) climbed 14.5% to $1.66. LightInTheBox named CEO Jian He as Chairman effective March 29 after Zhi Yan resigned due to personal reasons.
    • Fluence Energy, Inc. (NASDAQ:FLNC) gained 13.9% to $18.49. Goldman Sachs upgraded Fluence Energy from Neutral to Buy and raised the price target from $25 to $29.
    • Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) climbed 13.6% to $22.93. Arcturus Therapeutics recently reported better-than-expected Q4 EPS and sales results.
    • NaaS Technology Inc. (NASDAQ:NAAS) gained 13.1% to $8.79.
    • Mullen Automotive, Inc. (NASDAQ:MULN) rose 13.1% to $0.1176 after jumping 11% on Wednesday.
    • Emergent BioSolutions Inc. (NYSE:EBS) gained 11.5% to $10.43 after the FDA approved over-the-counter designation to the company's NARCAN nasal spray.
    • Alpine Acquisition Corporation (NASDAQ:REVE) shares rose 11.2% to $10.56.
    • RenovoRx, Inc. (NASDAQ:RNXT) shares gained 10.7% to $4.3189 after the company announced new data from Phase III clinical trial interim analysis.
    • Better Therapeutics, Inc. (NASDAQ:BTTX) surged 10.6% to $0.7034 after the company reported better-than-expected Q4 EPS results.
    • Cazoo Group Ltd (NYSE:CZOO) shares rose 9.4% to $2.6156 after jumping 15% on Wednesday.
    • Kohl's Corporation (NYSE:KSS) gained 7.2% to $23.65.

    Losers

    • mCloud Technologies Corp. (NASDAQ:MCLD) shares dipped 43% to $0.4101. mCloud announced receipt of Nasdaq notification letter regarding minimum bid price deficiency.
    • Sonida Senior Living, Inc. (NASDAQ:SNDA) fell 33.3% to $7.16 after reporting downbeat Q4 results.
    • AngioDynamics, Inc. (NASDAQ:ANGO) fell 24.3% to $9.38 after the company posted downbeat Q3 results and lowered FY23 outlook.
    • Semtech Corporation (NASDAQ:SMTC) fell 23.1% to $24.71 after posting downbeat Q4 earnings.
    • Dragonfly Energy Holdings Corp. (NASDAQ:DFLI) shares dipped 22.8% to $3.4299 after the company reported worse-than-expected Q4 sales.
    • Blue Star Foods Corp. (NASDAQ:BSFC) fell 22.2% to $0.1220.
    • Cyxtera Technologies, Inc. (NASDAQ:CYXT) dropped 22% to $0.5061. Starboard Value said on March 27, Jeff Smith resigned from board of Cyxtera and representatives of Starboard Value ceased serving as observers on board.
    • Bit Brother Limited (NASDAQ:BTB) fell 20.7% to $1.07.
    • China Automotive Systems, Inc. (NASDAQ:CAAS) dropped 19.9% to $4.8350. China Automotive Systems reported a fourth-quarter FY22 sales decline of 7.2% year-on-year to $128.80 million, missing the consensus of $138.46 million.
    • Laser Photonics Corporation (NASDAQ:LASE) fell 19% to $4.9699 after the company said it will postpone reporting its Q4 ended December 31, 2022.
    • Metropolitan Bank Holding Corp. (NYSE:MCB) fell 18.9% to $28.39.
    • LogicMark, Inc. (NASDAQ:LGMK) shares dropped 17.3% to $0.1610. LogicMark shares jumped over 39% on Wednesday after the company announced financial results for the year ended 2022.
    • G Medical Innovations Holdings Ltd (NASDAQ:GMVD) dipped 16.7% to $2.24.
    • Avidity Biosciences, Inc. (NASDAQ:RNA) dropped 16% to $16.96 as the company issued an update on Phase 1/2 MARINA trial of AOC 1001 in adults with myotonic dystrophy Type 1.
    • Franklin Covey Co. (NYSE:FC) fell 15.7% to $37.28 after the company reported worse-than-expected Q2 results.
    • Bed Bath & Beyond Inc. (NASDAQ:BBBY) fell 15% to $0.68 after the company entered a $300 million at the market offering program and issued weak Q4 guidance.
    • Codiak BioSciences, Inc. (NASDAQ:CDAK) fell 13.2% to $0.1823 after jumping over 10% on Wednesday. Codiak BioSciences voluntarily filed for protection under Chapter 11 bankruptcy.
    • TORM plc (NASDAQ:TRMD) fell 12.8% to $28.54 after the company reported commencement of a secondary public offering of 5 million of its Class A common shares by a selling shareholder.
    • Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) dropped 9.4% to $6.62.
    • ProQR Therapeutics N.V. (NASDAQ:PRQR) shares fell 7.5% to $2.33. ProQR Therapeutics filed prospectus relates to resale of up to 13.4 million shares by selling shareholders.
    • IHS Holding Limited (NYSE:IHS) fell 6.8% to $8.25. IHS Holding recently reported better-than-expected Q4 sales results.
    • Verint Systems Inc. (NASDAQ:VRNT) dropped 6.6% to $34.99 following Q4 resulst.

    Now Read This: Top 5 Industrials Stocks That Could Lead To Your Biggest Gains In March

    Get the next $ANGO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ANGO
    $ARCT
    $AXDX
    $BBBY

    CompanyDatePrice TargetRatingAnalyst
    Fluence Energy Inc.
    $FLNC
    4/17/2026$8.00Neutral → Sell
    UBS
    Metropolitan Bank Holding Corp.
    $MCB
    4/16/2026$97.00Neutral
    UBS
    Sonida Senior Living Inc.
    $SNDA
    4/13/2026$36.00Overweight
    Cantor Fitzgerald
    Palisade Bio Inc.
    $PALI
    4/9/2026$7.00Outperform
    Wolfe Research
    Sonida Senior Living Inc.
    $SNDA
    3/27/2026$39.00Outperform
    RBC Capital Mkts
    Phathom Pharmaceuticals Inc.
    $PHAT
    3/27/2026$18.00Equal Weight → Overweight
    Barclays
    Palisade Bio Inc.
    $PALI
    3/26/2026$7.00Buy
    H.C. Wainwright
    EVgo Inc.
    $EVGO
    3/25/2026Overweight → Neutral
    Analyst
    More analyst ratings

    $ANGO
    $ARCT
    $AXDX
    $BBBY
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Simanovsky Michael exercised 1,601,505 shares at a strike of $32.00 and bought $100,000,006 worth of shares (3,739,716 units at $26.74) (SEC Form 4)

    4 - SONIDA SENIOR LIVING, INC. (0001043000) (Issuer)

    3/13/26 7:54:44 PM ET
    $SNDA
    Hospital/Nursing Management
    Health Care

    Director Tabacco Joseph J Jr bought $102,200 worth of shares (20,000 units at $5.11) (SEC Form 4)

    4 - BED BATH & BEYOND, INC. (0001130713) (Issuer)

    3/12/26 8:32:43 PM ET
    $BBBY
    Catalog/Specialty Distribution
    Consumer Discretionary

    EVP & Chief Financial Officer Dougherty Daniel F bought $79,950 worth of shares (1,000 units at $79.95), increasing direct ownership by 3% to 32,197 units (SEC Form 4)

    4 - Metropolitan Bank Holding Corp. (0001476034) (Issuer)

    3/11/26 5:05:05 PM ET
    $MCB
    Major Banks
    Finance

    $ANGO
    $ARCT
    $AXDX
    $BBBY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Fluence downgraded by UBS with a new price target

    UBS downgraded Fluence from Neutral to Sell and set a new price target of $8.00

    4/17/26 8:08:09 AM ET
    $FLNC
    Industrial Machinery/Components
    Miscellaneous

    UBS initiated coverage on Metropolitan Bank with a new price target

    UBS initiated coverage of Metropolitan Bank with a rating of Neutral and set a new price target of $97.00

    4/16/26 9:27:25 AM ET
    $MCB
    Major Banks
    Finance

    Cantor Fitzgerald initiated coverage on Sonida Senior Living with a new price target

    Cantor Fitzgerald initiated coverage of Sonida Senior Living with a rating of Overweight and set a new price target of $36.00

    4/13/26 9:01:02 AM ET
    $SNDA
    Hospital/Nursing Management
    Health Care

    $ANGO
    $ARCT
    $AXDX
    $BBBY
    SEC Filings

    View All

    AngioDynamics Inc. filed SEC Form 8-K: Other Events

    8-K - ANGIODYNAMICS INC (0001275187) (Filer)

    4/23/26 4:59:50 PM ET
    $ANGO
    Medical/Dental Instruments
    Health Care

    Dragonfly Energy Holdings Corp. filed SEC Form 8-K: Other Events

    8-K - Dragonfly Energy Holdings Corp. (0001847986) (Filer)

    4/23/26 7:40:36 AM ET
    $DFLI
    Industrial Machinery/Components
    Miscellaneous

    SEC Form DEFA14A filed by Emergent BioSolutions Inc.

    DEFA14A - Emergent BioSolutions Inc. (0001367644) (Filer)

    4/22/26 4:50:05 PM ET
    $EBS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANGO
    $ARCT
    $AXDX
    $BBBY
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for VOQUEZNA issued to PHATHOM PHARMACEUTICALS INC

    Submission status for PHATHOM PHARMACEUTICALS INC's drug VOQUEZNA (ORIG-1) with active ingredient VONOPRAZAN FUMARATE has changed to 'Approval' on 07/17/2024. Application Category: NDA, Application Number: 218710, Application Classification: Type 9 - New Indication Submitted as Distinct NDA, Consolidated with Original NDA after Approval

    7/18/24 10:52:01 AM ET
    $PHAT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for VOQUEZNA TRIPLE PAK issued to PHATHOM PHARMACEUTICALS, INC

    Submission status for PHATHOM PHARMACEUTICALS, INC's drug VOQUEZNA TRIPLE PAK (ORIG-1) with active ingredient AMOXICILLIN; CLARITHROMYCIN; VONOPRAZAN has changed to 'Approval' on 05/03/2022. Application Category: NDA, Application Number: 215152, Application Classification: Type 1 - New Molecular Entity and Type 4 - New Combination

    5/11/22 10:51:07 AM ET
    $PHAT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for VOQUEZNA DUAL PAK issued to PHATHOM PHARMACEUTICALS, INC

    Submission status for PHATHOM PHARMACEUTICALS, INC's drug VOQUEZNA DUAL PAK (ORIG-1) with active ingredient AMOXICILLIN; VONOPRAZAN has changed to 'Approval' on 05/03/2022. Application Category: NDA, Application Number: 215153, Application Classification: Type 5 - New Formulation or New Manufacturer

    5/11/22 10:17:03 AM ET
    $PHAT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANGO
    $ARCT
    $AXDX
    $BBBY
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Eos Energy Enterprises Announces Date for First Quarter 2026 Financial Results and Conference Call; Announces Participation at Upcoming Investor Conferences

    EDISON, N.J., April 23, 2026 (GLOBE NEWSWIRE) -- Eos Energy Enterprises, Inc. (NASDAQ:EOSE) ("Eos" or the "Company"), an American energy company and the leading innovator in designing, sourcing, manufacturing, and providing zinc-based battery energy storage systems (BESS) manufactured in the United States, today announced it will release its first quarter 2026 financial results before the U.S. market opens on May 13, 2026. A conference call to discuss its results will take place the same morning at 8:30 a.m. Eastern Time. Eos partners with Say Technologies to allow retail and institutional shareholders to submit and vote on questions ahead of the earnings call. A selection of key question

    4/23/26 4:30:00 PM ET
    $EOSE
    Industrial Machinery/Components
    Miscellaneous

    Puma Biotechnology to Host Conference Call to Discuss First Quarter 2026 Financial Results

    Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PT/4:30 p.m. ET on Thursday, May 7, 2026, following the release of its first quarter 2026 financial results. The call may be accessed by dialing 1-877-709-8150 (domestic) or 1-201-689-8354 (international). Please dial in at least 10 minutes in advance and inform the operator that you would like to join the "Puma Biotechnology Conference Call." A live webcast of the conference call and presentation slides may be accessed on the Investors section of the Puma Biotechnology website at https://www.pumabiotechnology.com. A replay of the call will be available approximately one hour afte

    4/23/26 4:15:00 PM ET
    $PBYI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    RenovoRx Announces Pharmacokinetic and Pharmacodynamic Data Abstract Supporting the TAMP™ Therapy Platform Accepted for Presentation at the 2026 ASCO Annual Meeting

    MOUNTAIN VIEW, Calif., April 23, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. ("RenovoRx" or "the Company") (NASDAQ:RNXT), a life-sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, FDA-cleared drug-delivery device, is pleased to announce that an abstract submission from a pharmacokinetic (PK) and pharmacodynamic sub‑study of its ongoing Phase III TIGeR‑PaC clinical trial locally advanced pancreatic cancer has been accepted for presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. The abstract, entitled "The TIGeR-PaC Phase 3 III Clinical Trial Examining Intra-Arterial Gemcitabine Versus Intravenous Gem

    4/23/26 8:30:00 AM ET
    $RNXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANGO
    $ARCT
    $AXDX
    $BBBY
    Leadership Updates

    Live Leadership Updates

    View All

    Metropolitan Commercial Bank Expands Florida Presence, Adds Jessica Raffo as Director of Association Banking

    Metropolitan Commercial Bank ("MCB" or the "Bank") today announced that Jessica Raffo has joined the Bank as Vice President and Director of Association Banking for the Florida region, further strengthening the Bank's expansion across the state. In this role, Ms. Raffo will lead the growth of MCB's Association Banking platform, working closely with the Bank's teams in Miami and West Palm Beach to expand client relationships, drive new business development, and support lending initiatives across the condominium and homeowner association sectors. She will play a key role in advancing MCB's relationship-driven approach and building scalable growth infrastructure throughout Florida. Ms. Raff

    4/20/26 7:05:00 AM ET
    $MCB
    Major Banks
    Finance

    Premium In-Lobby Media Network Coming to 285 Movie Theatres Nationwide in a New Initiative from National CineMedia and Creative Realities

    National CineMedia (NASDAQ:NCMI) ("NCM"), the leading cinema advertising platform in the U.S. and a leading provider of digital signage, experiential solutions, and media network management, and Creative Realities, Inc. (NASDAQ:CREX) ("CRI"), a leading provider of digital media and AdTech solutions, today announced a new partnership to significantly expand and modernize AMC Theatres' (NYSE:AMC) in-lobby media footprint across 285 locations nationwide. This new initiative will turn the lobby at the participating theaters into a network of digital displays, including multiple 75-inch screens per location, that will deliver high-impact video, brand storytelling, and interactive experiences.

    4/13/26 8:00:00 AM ET
    $AMC
    $CNK
    $CREX
    Movies/Entertainment
    Consumer Discretionary
    EDP Services
    Technology

    Bed Bath & Beyond Names Veteran Retail Operator Amy Sullivan President

    Bed Bath & Beyond, Inc. (NYSE:BBBY) ("Bed Bath & Beyond" or the "Company"), owner of Bed Bath & Beyond, Overstock, buybuy BABY, Kirkland's, and a blockchain asset portfolio, today announced the appointment of Amy Sullivan as President, effective immediately, as the Company accelerates its next phase of disciplined growth. Sullivan is a merchant and operator who built her career across some of retail's most recognized brands, including JCPenney, Kohl's, Lands' End, Express, and Lane Bryant, before joining Kirkland's in 2012, where she rose from divisional merchandise manager to President and CEO. As CEO of The Brand House Collective, the operating entity she led through its transformation

    4/6/26 8:30:00 AM ET
    $BBBY
    Catalog/Specialty Distribution
    Consumer Discretionary

    $ANGO
    $ARCT
    $AXDX
    $BBBY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Detz Kevin

    4 - SONIDA SENIOR LIVING, INC. (0001043000) (Issuer)

    4/22/26 9:22:50 PM ET
    $SNDA
    Hospital/Nursing Management
    Health Care

    SEC Form 4 filed by Ribar Brandon

    4 - SONIDA SENIOR LIVING, INC. (0001043000) (Issuer)

    4/22/26 9:20:28 PM ET
    $SNDA
    Hospital/Nursing Management
    Health Care

    SEC Form 4 filed by Kenney Stephanie

    4 - Atrium Therapeutics, Inc. (0002093101) (Issuer)

    4/22/26 5:54:12 PM ET
    $RNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANGO
    $ARCT
    $AXDX
    $BBBY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Eos Energy Enterprises Inc.

    SC 13D/A - Eos Energy Enterprises, Inc. (0001805077) (Subject)

    12/17/24 2:48:02 PM ET
    $EOSE
    Industrial Machinery/Components
    Miscellaneous

    Amendment: SEC Form SC 13D/A filed by Accelerate Diagnostics Inc.

    SC 13D/A - Accelerate Diagnostics, Inc (0000727207) (Subject)

    12/5/24 5:13:13 PM ET
    $AXDX
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Amendment: SEC Form SC 13D/A filed by LogicMark Inc.

    SC 13D/A - LogicMark, Inc. (0001566826) (Subject)

    12/3/24 3:35:39 PM ET
    $LGMK
    Industrial Specialties
    Health Care

    $ANGO
    $ARCT
    $AXDX
    $BBBY
    Financials

    Live finance-specific insights

    View All

    Eos Energy Enterprises Announces Date for First Quarter 2026 Financial Results and Conference Call; Announces Participation at Upcoming Investor Conferences

    EDISON, N.J., April 23, 2026 (GLOBE NEWSWIRE) -- Eos Energy Enterprises, Inc. (NASDAQ:EOSE) ("Eos" or the "Company"), an American energy company and the leading innovator in designing, sourcing, manufacturing, and providing zinc-based battery energy storage systems (BESS) manufactured in the United States, today announced it will release its first quarter 2026 financial results before the U.S. market opens on May 13, 2026. A conference call to discuss its results will take place the same morning at 8:30 a.m. Eastern Time. Eos partners with Say Technologies to allow retail and institutional shareholders to submit and vote on questions ahead of the earnings call. A selection of key question

    4/23/26 4:30:00 PM ET
    $EOSE
    Industrial Machinery/Components
    Miscellaneous

    Puma Biotechnology to Host Conference Call to Discuss First Quarter 2026 Financial Results

    Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PT/4:30 p.m. ET on Thursday, May 7, 2026, following the release of its first quarter 2026 financial results. The call may be accessed by dialing 1-877-709-8150 (domestic) or 1-201-689-8354 (international). Please dial in at least 10 minutes in advance and inform the operator that you would like to join the "Puma Biotechnology Conference Call." A live webcast of the conference call and presentation slides may be accessed on the Investors section of the Puma Biotechnology website at https://www.pumabiotechnology.com. A replay of the call will be available approximately one hour afte

    4/23/26 4:15:00 PM ET
    $PBYI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Atrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb Under Global Cardiovascular Collaboration

    SAN DIEGO, April 23, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (NASDAQ:RNA) (the "Company"), a biopharmaceutical company dedicated to delivering RNA therapeutics directly to the heart, announced today it has earned a $15 million development milestone payment from Bristol Myers Squibb (NYSE:BMY). The milestone was achieved upon the successful delivery of a development candidate for the first licensed compound targeting a cardiology indication under the Company's ongoing collaboration. "This milestone marks a meaningful step forward for Atrium, further expanding our RNA deliv

    4/23/26 8:00:00 AM ET
    $BMY
    $RNA
    Biotechnology: Pharmaceutical Preparations
    Health Care